

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS FO Box 1430 Alexandria, Virginia 22313-1450 www.tepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/541,786	08/29/2006	Barry Douglas Moore	031749/295113	4147
826 7590 10913/2010 ALSTON & BIRD LLP BANK OF AMERICA PLAZA 101 SOUTH TRYON STREET, SUITE 4000 CHARLOTTE. NC 2828-04000			EXAM	IINER
			YOUNG, MICAH PAUL	
			ART UNIT	PAPER NUMBER
CHILLOTTE	4110 20200 1000		1618	
			MAIL DATE	DELIVERY MODE
			10/13/2010	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.	Applicant(s)	Applicant(s)		
10/541,786	MOORE ET AL.			
Examiner	Art Unit			
MICAH-PAUL YOUNG	1618			

	MICAH-PAUL YOUNG	1618			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address					
Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.38(a). In no event, however, may a reply be timely filed - If NO period for reply aspecified allows of the communications of the communication					
Status					
1) Responsive to communication(s) filed on	– action is non-final. ice except for formal matters, pro		e merits is		
Disposition of Claims					
4) Claim(s) 100-136 is/are pending in the applicat 4a) Of the above claim(s) is/are withdrav 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 100-136 are subject to restriction and	vn from consideration.				
Application Papers					
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) acc Applicant may not request that any objection to the c Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Ex	epted or b) objected to by the l drawing(s) be held in abeyance. See on is required if the drawing(s) is obj	a 37 CFR 1.85(a). jected to. See 37 C			
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior	s have been received. s have been received in Applicati ity documents have been receive (PCT Rule 17.2(a)).	on No ed in this National	Stage		
Attachment(s)					
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Pager Note Mail Date Programmer Statement(s) (PTO/SB/08)	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal F	ite			

Attachment(s)		
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summary (PTO-413) Paper No(s)/Mail Date.	
Information Disclosure Statement(s) (FTO/SB/00) Paper No(s)/Mail Date	5) Notice of Informal Patent Application 6) Other:	
S. Patent and Trademark Office		_

Application/Control Number: 10/541,786

Art Unit: 1618

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 100-111, drawn to a continuous method of forming particle comprising providing an aqueous solution comprising a coprecipitant molecule, and a bioactive molecule, where the solution is mixture of the molecules is mixed with a greater volume of water and the solvent is isolated.

Group II, claim(s) 112-136, drawn to a pharmaceutical formulation comprising a crystalline core and drug coating.

The groups of inventions listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The special technical feature of group II is in the crystalline particles that have a drug coating on the surface. These particles are known in the art as seen by Toback et al US 2003/0158115. Toback teaches valine crystals [Table 1] coated with albumin [0127]. These disclosures teach the specific technical feature of group II and is different from the special technical feature of group I requiring a continuous method of particle formation.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

Application/Control Number: 10/541,786

Art Unit: 1618

The election of an invention or species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse. Traversal must be presented at the time of election in order to be considered timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable on the elected invention or species.

Should applicant traverse on the ground that the inventions have unity of invention (37 CFR 1.475(a)), applicant must provide reasons in support thereof. Applicant may submit evidence or identify such evidence now of record showing the inventions to be obvious variants or clearly admit on the record that this is the case. Where such evidence or admission is provided by applicant, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MICAH-PAUL YOUNG whose telephone number is (571)272Art Unit: 1618

0608. The examiner can normally be reached on Monday-Friday 8:00-5:30; every other Friday

off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Michael G. Hartley can be reached on 571-272-0616. The fax phone number for the

organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would

like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Michael G. Hartley/

Supervisory Patent Examiner, Art Unit 1618

/MICAH-PAUL YOUNG/ Examiner, Art Unit 1618